2020 Alzheimer’s Drug Discovery Foundation (4 Program Areas open for application)

Unrestricted funding opportunity

From: Office of Faculty Affairs, Office of the Provost
Coordinator: Lucy Grantham, Director, Foundation Relations (lucy.grantham@emory.edu)
Website: https://www.alzdiscovery.org/research-and-grants/funding-opportunities

Submission Limitations: None, however, please contact your RAS unit *and* Lucy Grantham to inform them of your intent to submit
Foundation Deadline: October 11, 2019 for Letters of Intent in the 4 funding areas described below
November 8, 2019 for Invited Full Proposal

Opportunity Details: The Alzheimer’s Drug Discovery Foundation (ADDF) supports promising research projects from around the world to develop new drugs for Alzheimer’s and related dementias, including vascular, Lewy body, and frontotemporal dementias. The goal is to accelerate the development of therapies through four core areas: Drug discovery, Clinical trials, Biomarkers, and Prevention

The ADDF is interested in novel therapeutic approaches, including small molecules, biologics, and gene therapies. Because the mechanisms underlying Alzheimer’s disease and related dementias are varied and complex, ADDF maintains a diverse portfolio of drug targets.

Four funding opportunities are currently open:

1. **Program to Accelerate Clinical Trials (PACT):** This RFP funds early-stage clinical trials through phase 2 for novel drug candidates, proof-of-concept trials in patients for repurposed/repositioned drugs, and regulatory studies for IND/CTA preclinical packages and drug manufacturing for later stage trials. [https://www.alzdiscovery.org/research-and-grants/funding-opportunities/pact](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/pact)
   **Average Award:** Up to $5 million based on stage and scope of research.

2. **Neuroimaging and CSF Biomarker Development:** This RFP supports the development and validation of neuroimaging and CSF biomarkers to enhance clinical trials for Alzheimer’s disease, related dementias, and cognitive aging. [https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers)
   **Average Award:** $150,000-$600,000 based on stage and scope of research. Larger amounts will be considered for PET ligand development for regulatory or clinical work.

3. **Prevention beyond the Pipeline:** This RFP supports comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. [https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline)
   **Average Award:** $50,000-$100,000 for epidemiological analyses based on scope of research. Up to $3 million for clinical trials based on stage and scope of research.

4. **Drug Discovery:** This RFP supports programs advancing lead molecules to clinical candidate selection or building preclinical evidence in relevant animal models for repurposed/repositioned drugs. [https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-discovery](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-discovery)
   **Average Award:** $150,000-$600,000 based on stage and scope of research.

Eligibility: Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits - Industry partnerships are strongly encouraged - and biotechnology companies.

Application Components: Submit the LOI through the ADDF Funding Portal [https://addf.fluxx.io/user_sessions/new](https://addf.fluxx.io/user_sessions/new) Along with contact and project information, the LOI will include: Scientific Rationale and Background (300 words maximum), Specific Aims (300 words maximum), and Summary of Key Supporting Data (300 words maximum).